Compare Main Street Capital Corporation (MAIN) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Nuvalent Inc — how do they compare? Main Street Capital Corporation trades at $54.94 (market cap $5.08B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Nuvalent Inc is the larger of the two by market cap, and Main Street Capital Corporation pays a 8.02% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| MAIN | NUVL | |
|---|---|---|
Market Cap | $5.08B | $9.81B |
Sector | Financials | Technology |
52-Week High | $67.54 | $123.96 |
52-Week Low | $49.63 | $72.16 |
Dividend Yield | 8.02% | — |
Enterprise Value | — | $8.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Main Street Capital (MAIN) trades at $54.59, down 1.41% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.93, missing expectations of $1.01, while Q4 2025 beat estimates. Revenue for 2025 was $591.85M with a net income margin of 83.36%, though 2026 projections show a decline to $526M. Analysts maintain a consensus price target of $57.75 with a 'Hold' rating predominance. Recent news highlights MAIN's dividend sustainability amid softening earnings.
MAIN offers a stable dividend yield but faces earnings pressure and revenue decline projections for 2026. The stock's valuation appears reasonable with a P/E of 11.66, yet investor caution is warranted due to mixed earnings performance and potential headwinds from Fed rate cuts impacting BDC earnings. Upside exists if the company meets or exceeds future EPS expectations, supported by its internal management cost advantage.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, with a bullish technical signal from moving averages but overbought oscillators. The company reported a net loss of $425.38 million for 2025 and negative cash flow from operations. Recent news is dominated by GSK's proposed acquisition of Nuvalent for $124 per share, announced in June 2026, which is under investigation by multiple law firms for fairness to shareholders.
The investment outlook is heavily influenced by the pending acquisition. While analyst consensus shows no sell ratings, the stock price is near the offer price, limiting upside. Key risks include the deal's completion and the company's ongoing losses. The primary opportunity is the acquisition premium, but fundamental challenges persist absent the deal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
